Trapidil-eluting stents for coronary revascularization in patients with coronary heart disease

The purpose of the 19-month clinical angiography-controlled prospective study was to evaluate safety and anti-ischemic efficacy of the endovascular coronary revascularization via implantation of the Trapidil eluting stents (TES) in patients with coronary heart disease (CHD). 58 patients (the average age of 54.7±9.4 years) with exertional angina after acute myocardial infarction (AMI) were prospectively studied. All patients were taking anti-ischemic antihypertensive medications and two anti-platelet aggregation drugs. TES were implanted in all patients. The study evaluated the life quality, recurrence rate of stenocardia, myocardial infarction, repeated revascularization due to artery restenosis and other unfavorable cardiovascular events such as: death, stent thrombosis, lethal AMI, cerebral stroke, impaired cardiac function, and indications for repeated hospitalization. The study showed that stenting of coronary arteries with TES in patients with CHD after AMI was safe and had high anti-ischemic efficacy. In a later part of the study (19±8 months after the beginning), high clinical anti-ischemic efficacy of endovascular revascularization was found in 65.5% of cases. According to data of follow-up coronary angiography, the rate of isolated stent restenosis was diagnosed in 10.3% of patients. In 12% of the cases, the stent restenosis was combined with progression of coronary arterial atherosclerosis de novo. Survival rate in the patients after the revascularization was 100%. There were no cases of stent thrombosis in the patients.